



05/07/04

1632

SEQUENCE LISTINGS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Michael Young et al.**

Art Unit No.: **1632**

Serial No.: **10/081,400**

Examiner: **Woitach, Joseph T**

Filed: **02/20/2002**

For: **Erythropoietin Analog-Human Serum Albumin Fusion**

Atty. Docket No.: **GTC-6D**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT


Sir:

Responsive to the Office Action mailed April 9, 2004, Applicant elects the invention of Group I drawn to erythropoietin-serum albumin fusion protein, without traverse. The invention of Group II (claims 51 and 52) are cancelled as directed to non-elected subject matter, however Applicant reserves the right to file an additional application covering the subject matter as claimed in Group II.

Respectfully submitted,

Dated: 5/6/04

By:


Byron V. Olsen, Reg. No. 42,960
Attorney for Applicants
GTC Biotherapeutics, Inc.
175 Crossing Blvd., Suite 410
Framingham, MA 01702
Tel. #(508) 370-5150 Fax #(508) 370-3797

CERTIFICATE OF MAILING BY EXPRESS MAIL

I hereby certify that under 37 CFR §1.10 that this correspondence is being deposited on May 6, 2004 with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Kristin Kaberry